Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Pharmacy Formulary Coverage Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    2026 Formulary (Drug List) — Pharmacy Coverage Criteria

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the HealthPartners pharmacy drug list (formulary) effective January 1, 2026; informs members and providers about covered medicines, tiers, specialty designations, limits, and prior authorization/step-therapy programs.

    Policy Summary
    PayerHealthPartners
    Policy2026 Formulary (Drug List) — Pharmacy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual formulary publication (no material changes)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for any product listed with 'PA' before dispensing to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    QuarterlyFormulary review frequency
    Tiers 1–7Drug tiers
    multiplePrior Authorization (PA)
    severalQuantity Limits (QL)
    Specialty pharmacySpecialty routing

    Coverage Criteria

    Quantity Limit Review Criteria

    Coverage decisions and overrides

    Quantity limit override: Requests above the quantity limit will be reviewed for medical necessity and must include evaluation of the diagnosis, alternatives previously tried, prior use of the requested product within the quantity limit, and evidence of efficacy and safety at the quantity requested.QL exceeded

    Supports prior authorization review

    Step Therapy Coverage

    Step therapy coverage logic

    Step therapy requirement: A medicine with step therapy will be covered if the member has already tried the required prior medicine(s); if prior steps have not been completed, prior approval from HealthPartners is required before the medicine will be covered at the lower cost-share.prior trial of specified agents
    Policy Summary
    PayerHealthPartners
    Policy2026 Formulary (Drug List) — Pharmacy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual formulary publication (no material changes)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for any product listed with 'PA' before dispensing to ensure coverage.
    SourceLink
    On This Page
    Coverage CriteriaFormulary Listings and Coding ExamplesProvider Actions and Authorization RequirementsDefinitions and AbbreviationsInitial Therapy CriteriaStep Therapy RulesQuantity Limits (Selected Items)Site of Care and Specialty Pharmacy RoutingBackground

    Approval needed if prior steps not met

    Formulary administrative criteria

    Coverage and administrative requirements as listed for products in this section

    Formulary entries: Products are listed with a Drug Tier and 'Requirements Limits' flags (examples shown: ACA, PA, QL, S, ONC, TD). Coverage for each product follows the listed requirement: ACA indicates mandated/ACA-related coverage, PA indicates prior authorization is required before coverage, QL indicates a numeric quantity limit, and S/ONC/TD indicate specialty/program routing or trial distribution requirements.

    Administrative flags reflect coverage pathways; no clinical medical necessity criteria are provided in these chunks.

    Coverage stance by formulary entry

    Formulary coverage and requirements as listed per product entry

    Entry-level: Each product row indicates Drug Tier and Requirements Limits; coverage is subject to those stated requirements. Examples: contraceptives and related devices marked 'ACA' are covered under ACA provisions; products marked 'PA' require prior authorization before coverage; products with 'QL' are limited to the stated quantity (e.g., ANNOVERA QL 1 per 273 days; emergency oral levonorgestrel QL 3 per 30 days; condoms QL 60 per 30 days).

    Reflects product-level coverage stance as listed in the formulary table.

    Failure to obtain required Prior Authorization (PA) may result in a prescription not being covered under the HealthPartners pharmacy benefit. Drugs that are flagged with PA in the formulary must have prior approval from the payer before coverage will be provided.

    Within the provided formulary excerpts there are no explicit medical exclusions stated. Product rows show administrative flags such as PA, QL and ACA, but the text in these chunks does not list medicines as specifically excluded for medical reasons.

    The excerpted lines do not present explicit exclusion statements. Entries list device and product coverage annotations (for example ACA, QL, PA) but do not identify any products as expressly excluded from coverage for clinical or medical-necessity reasons.

    This section only shows product-level requirement and limit codes (e.g., PA, QL) for ophthalmic and related entries. There are no explicit exclusion rules stated in the provided lines — only the per-product requirement/limit annotations are shown.

    Within the supplied extract there are no statements identifying items as 'not medically necessary'. The lines include requirement flags and tiering but do not contain explicit 'not medically necessary' determinations.

    Formulary Listings and Coding Examples

    Formulary drug listings and limits (examples)mixedCovered
    NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON 300 MGlisted with Drug Tier = 3, Requirements Limits = PA
    nystatin oral suspension 100,000 unit/mllisted with Drug Tier = 3, Requirements Limits = QL (480 per 30 days)
    posaconazole oral suspension 200 mg/5 ml (40 mg/ml)listed with Drug Tier = 3, Requirements Limits = PA
    voriconazole oral tablet 200 mg, 50 mglisted with Drug Tier = 3, Requirements Limits = PA
    abacavir oral tablet 300 mglisted with Drug Tier = 3, Requirements Limits = .
    acyclovir oral tablet 400 mg, 800 mglisted with Drug Tier = 3, Requirements Limits = .
    Sample formulary entriesmixed
    nystatin oral suspension 100,000 unit/mlListed with Drug Tier = 3; QL (480 per 30 days)
    posaconazole oral suspension 200 mg/5 ml (40 mg/ml)Drug Tier = 3; Requirements Limits = PA
    voriconazole oral tablet 200 mg, 50 mgDrug Tier = 3; Requirements Limits = PA
    abacavir oral solution 20 mg/mlDrug Tier = 3
    BIKTARVY ORAL TABLET 30-120-15 MGDrug Tier = 3
    EPCLUSA ORAL TABLET 200-50 MGRequirements Limits = PA; S
    HARVONI ORAL TABLET 45-200 MGRequirements Limits = PA; S
    LEDIPASVIR-SOFOSBUVIR ORAL TABLET 90-400 MGDrug Tier = 6; Requirements Limits = PA; S
    MAVYRET ORAL TABLET 100-40 MGDrug Tier = 6; Requirements Limits = PA; S
    Antiviral dose packs and QLsmixedCovered
    oseltamivir oral capsule 30 mgDrug Tier = 3; QL (20 per 30 days)
    oseltamivir oral capsule 45 mg, 75 mgDrug Tier = 3; QL (10 per 30 days)
    PAXLOVID ORAL TABLETS, DOSE PACK 150Drug Tier = 3; QL (4 per 1 day)
    PAXLOVID ORAL TABLETS, DOSE PACK 300 MGDrug Tier = 3; QL (6 per 1 day)
    Misc antiinfectives with PA/QLmixed
    ALINIA ORAL SUSPENSION FOR RECONSTITUTION 100 MG/5 MLDrug Tier = 4; Requirements Limits = PA; QL (180 per 30 days)
    linezolid oral tablet 600 mgDrug Tier = 3; Requirements Limits = QL (2 per 1 day)
    XIFAXAN ORAL TABLET 200 MG, 550 MGDrug Tier = 3; Requirements Limits = PA
    Antibiotics (selected entries)mixed
    amoxicillin oral suspension for reconstitution 125 mg/5 mlDrug Tier = 3
    amoxicillin oral tablet 500 mgDrug Tier = 3
    amoxicillin-pot clavulanate oral tablet 250-125 mgDrug Tier = 3
    ampicillin oral capsule 500 mgDrug Tier = 3
    dicloxacillin oral capsule 250 mgDrug Tier = 3
    Fluoroquinolones & Sulfonamidesmixed
    ciprofloxacin hcl oral tablet 250 mgDrug Tier = 3
    levofloxacin oral tablet 250 mgDrug Tier = 3
    moxifloxacin oral tablet 400 mgDrug Tier = 3
    sulfadiazine oral tablet 500 mgDrug Tier = 4; Requirements Limits = PA
    sulfamethoxazole-trimethoprim oral tablet 400-80 mgDrug Tier = 3
    Antineoplastic & immunosuppressant agentsmixed
    abiraterone oral tablet 250 mgRequirements Limits = PA; ONC; TD; S
    anastrozole oral tabletDrug Tier = 7; Requirements Limits = ONC
    capecitabine oral tablet 150 mgRequirements Limits = ONC; S
    dasatinib oral tablet 100 mgRequirements Limits = PA; ONC; TD; S
    everolimus (antineoplastic) oral tablet 10 mgRequirements Limits = PA; ONC; TD; S; QL (1 per 1 day)
    Targeted cancer therapiesmixed
    ROZLYTREK ORAL CAPSULE 100 MGRequirements Limits = PA; ONC; TD; S; QL
    TAGRISSO ORAL TABLET 40 MGDrug Tier = 7; Requirements Limits = PA; ONC; TD; S; QL (1 per 1 day)
    TAFINLAR ORAL CAPSULE 50 MGRequirements Limits = PA; ONC; S
    Product entries (no billing codes in this excerpt)mixed
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes present in these chunks; only product names, formulations, and tiers are listed.
    Formulary products (examples)NDC|product
    XELJANZ XR 11 MG, 22 MGXELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR
    Selected products with PA notedproduct
    BIJUVABIJUVA ORAL CAPSULE 0.5-100 MG, 1-100 MG
    DUAVEEDUAVEE ORAL TABLET 0.45-20 MG
    MYFEMBREEMYFEMBREE ORAL TABLET 40-1-0.5 MG
    ORIAHNNORIAHNN ORAL CAPSULE, SEQUENTIAL 300-1-0.5MG(AM) /300 MG(PM)
    OSPHENAOSPHENA ORAL TABLET 60 MG
    Contraceptive devices and patchesproductCovered
    ANNOVERAANNOVERA VAGINAL RING 0.15-0.013 MG/24 HOUR
    TWIRLATWIRLA TRANSDERMAL PATCH WEEKLY 120-30 MCG/24 HR
    VCFVCF CONTRACEPTIVE FILM VAGINAL FILM 28 %
    Oral contraceptives — tiers and limitsmixedCovered
    QL (3 per 30 days)Quantity limit for certain oral contraceptives (3 per 30 days)
    Drug Tier = 3Tier assignment for listed oral contraceptives
    Requirements Limits = ACACoverage requirement/limit code (ACA)
    Ophthalmic products — tiers and requirement codesmixedCovered
    PAPrior authorization required (appears for several ophthalmic agents)
    QL (5 per 30 days)Quantity limit for CYSTADROPS
    QL (15 per 30 days)Quantity limit for CYSTARAN
    SSpecialty or site restriction
    Drug Tier = 4Tier assignment for some ophthalmic products (e.g., LEVOFLOXACIN 0.5% listed as Tier 4)
    inv-25: nystatin oral suspension limit — 480 per 30 days
    Productnystatin oral suspension 100,000 unit/ml — QL 480 per 30 days
    Limit value480 per 30 days
    Formulary tier/contextListed as Drug Tier = 3 with Requirements Limits = QL
    inv-26: Quantity limits examples
    Nystatin suspensionQL 480 per 30 days
    Oseltamivir oral capsule 30 mgQL 20 per 30 days
    ALINIA oral suspension 100 mg/5 mLQL 180 per 30 days
    inv-27: Quantity limits examples
    Tetracycline oral capsule 250 mgQL 56 per 30 days
    Fosfomycin tromethamine oral packet 3 gramQL 3 per 30 days
    Formulary contextBoth entries show explicit QL values in the Requirements Limits column
    inv-28: Example Quantity Limits — includes per day and per 30 day fractions
    Per-day fractional QLs (examples)QL values expressed as fractions per day (e.g., QL 1 per 1 day; QL 2 per 1 day)
    Per-30-day QLs (example)QL entries also shown as 'per 30 days' in the table
    Usage noteFormulary displays QL using both per-day fractions and per-30-day totals depending on product presentation
    inv-29: Quantity Limits examples — multiple fractional/day examples
    Fractional/day examplesQLs expressed as fractional per day values (e.g., 0.4 per 1 day; 0.429 per 1 day; 0.167 per 1 day)
    Higher per-day QLsExamples include QL 4 per 1 day and QL 2 per 1 day for certain products
    Extended-period examplesSome QLs reference multi-day denominators (e.g., 28 per 273 days) as shown in the table
    inv-30: Acyclovir topical quantity limit — 15 per 30 days
    Productacyclovir topical ointment 5% — QL 15 per 30 days
    Formulary tier/contextListed with Requirements Limits = QL in topical antivirals section
    Coverage implicationRequests exceeding QL may be reviewed for medical necessity per documentation guidance
    inv-31: Nystatin/topical powder quantity limit — 240 per 30 days
    Productnystatin topical powder 100,000 unit/gram — QL 240 per 30 days
    Related topical entriesTopical antifungals show QL examples such as mupirocin 44 per 30 days and other QLs per day or per 30 days
    Formulary contextTopical powders/creams display QL in Requirements Limits column
    inv-32: Baqsimi / glucagon kit quantity limit — 4 per 30 days
    BAQSIMI nasal spray 3 mgQL 4 per 30 days
    Glucagon emergency kit (human)QL 4 per 30 days
    Formulary noteEmergency glucagon products are documented with QL entries in the formulary table
    inv-33: Quantity limits examples — SHINGRIX QL 1 per 30 days; biologics as per-day fractions
    SHINGRIX (vaccine)QL 1 per 30 days (ACA-designated) — example
    BiologicsMany biologics display fractional per-day QL values (e.g., 0.129 per 1 day in selected entries)
    Provider actionProducts with QL require adherence to listed quantities; PA may also apply for biologics
    inv-34: Quantity limits examples — 2 per 1 day; 60 per 30 days; 1 per 273 days; etc.
    Common examplesQL 2 per 1 day; QL 60 per 30 days; QL 1 per 273 days — shown in contraceptive/device and other product rows
    Emergency contraceptionlevonorgestrel oral tablet 1.5 mg — QL 3 per 30 days (example of 30-day QL)
    Long-interval deviceANNOVERA vaginal ring — QL 1 per 273 days (device-specific QL)

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required — Flagged Products

    Certain medicines listed in the drug table are designated with requirement flags (for example: PA, S, ST, QL, ONC, ACA). When a product is marked PA (Prior Authorization) the prescriber or member must obtain prior authorization from HealthPartners before the drug will be covered under the pharmacy benefit. Failure to secure required PA may result in claim denial or non‑coverage.

    • PA indicates Prior Authorization is required before coverage.
    • S indicates specialty routing or specialty program requirements.
    • ST indicates Step Therapy — preferred alternatives must be tried first.
    • QL indicates a Quantity Limit — requests above the listed amount will be reviewed.
    Prior Authorization

    Prior Authorization Required for Many Agents

    Many specialty, oncology, injectable, and select oral agents in the formulary are subject to prior authorization. Examples include oral oncology agents, biologics, palforzia allergy products, select antiviral and specialty antiviral agents, and many GLP‑1 / diabetes agents (liraglutide, semaglutide products, tirzepatide, etc.). For these products the Requirements Limits field will include PA, often together with S (specialty) and/or QL.

    • Specialty and oncology agents commonly show PA; some also require specialty routing (S) and have quantity limits (QL).
    • Selected antiviral regimens and hepatitis C agents include PA and may also include S.
    • Selected GLP‑1 and other diabetes agents are listed with Requirements Limits = PA and may have QLs.
    Documentation Required

    Documentation and Quantity‑Limit Overrides

    Prescribers must submit supporting documentation with PA requests and for any requests that exceed a product’s quantity limit. Documentation should demonstrate medical necessity and include diagnosis, prior therapies tried (including dates and outcomes), relevant lab or clinical data, and rationale for the requested quantity or agent.

    • Requests above a QL are reviewed for medical necessity and require documentation of diagnosis and alternatives tried.
    • Program‑specific flags (ONC, TD, S, QL) require corresponding documentation per HealthPartners procedures.
    • When a product is flagged PA or S, include clinical rationale and any specialty pharmacy routing details in the submission.
    Denial Risk

    Denial Risk — PA and Quantity Limits

    PA and QL flags on the drug list are operational triggers — claims submitted for products marked PA without an approved authorization or for quantities exceeding the listed QL are at risk of denial at point of adjudication. Providers should verify authorization status before dispensing and follow HealthPartners’ PA submission process.

    • Claims for PA‑listed drugs may be denied if an authorization is not in place.
    • Claims exceeding QL will be subject to review and may be denied without adequate supporting documentation.
    • Specialty program flags (S) and step‑therapy flags (ST) can also trigger coverage edits or channeling to a specialty pharmacy.
    Step Therapy

    Step Therapy and Specialty Program Indicators

    Step therapy and specialty program indicators appear on some entries. ST indicates a step‑therapy requirement (for example, certain PCSK9/REPATHA entries), and S indicates specialty pharmacy routing or program participation. Where step therapy applies, members must have trialed required alternatives or obtain an exception/approval.

    • ST = Step Therapy; patient must try specified preferred medicines first or obtain approval.
    • S = Specialty program or specialty pharmacy routing required.
    • If step therapy or specialty routing is listed, include prior treatment history and rationale when requesting PA.

    Definitions and Abbreviations

    inv-94: Specialty medicines — specialty medicines definition/notes
    DefinitionSpecialty medicines: prescribed for chronic/complex diseases, often high-cost, requiring more management and specialty pharmacy fills
    Benefit implicationSpecialty medicines are often covered under a different benefit and must be filled at a specialty pharmacy
    Administration noteProviders and members should check plan benefits for specialty medicine coverage details
    inv-95: Formulary abbreviations — PA, ST, QL, AL, ONC, OP, TD
    PAPrior Authorization
    STStep Therapy
    QLQuantity Limit
    ALAge Limit
    ONCOncology Benefit
    inv-96: PA — Prior Authorization definition
    TermPrior Authorization (PA) — coverage requires approval prior to dispensing
    ImplicationPrescriber must obtain authorization per plan processes or coverage may be denied
    Table usePA appears in the Requirements Limits column next to affected products
    inv-97: QL — Quantity Limit definition
    TermQuantity Limit (QL) — maximum allowed quantity in specified time period
    FormatQL values shown as numeric totals per time (e.g., per 30 days) or as fractional per-day values
    Clinical actionRequests above QL reviewed for medical necessity and require supporting documentation
    inv-98: S — Specialty or program-specific requirement (table indicator)
    IndicatorS — Specialty or program-specific requirement (table indicator) — appears alongside PA/QL for some products
    MeaningMay indicate specialty routing, step/supplemental program, or specialty pharmacy handling
    ExamplesUsed for oncology and other specialty product rows in the formulary table
    inv-99: ACA — Administrative/coverage annotation (table start reference)
    TermACA — Affordable Care Act annotation indicating preventive/mandated coverage for specified products
    Table usageAppears in Requirements Limits to denote ACA-mandated coverage for vaccines, contraceptives, some smoking cessation products
    Coverage implicationACA-designated products may have different coverage rules; see table header and plan details
    inv-100: Requirement/limit codes — mapping summary (PA, QL, ONC, TD)
    PAPrior Authorization — requires pre-approval before coverage
    QLQuantity Limit — numeric limit shown per time period
    ONC/TD/SONC = Oncology Benefit; TD = Trial Drug; S = Specialty — program/handling flags
    inv-101: PA — PA flag appearing in Requirements Limits
    PA flagIndicates prior authorization requirement appearing in the Requirements Limits field
    ImplicationClaims without PA may be denied for PA-flagged products
    Provider actionObtain PA per HealthPartners processes before dispensing
    inv-102: QL — Quantity Limit examples in Requirements Limits
    QL examplesQuantity Limits shown numerically (e.g., '1 per 1 day', '4 per 30 days'); may be per day fractions or per 30 days
    Table locationQL appears in Requirements Limits column next to product rows
    ImplicationRequests exceeding QL will be reviewed for medical necessity
    inv-103: ONC — Oncology-related requirement flag
    PAPrior Authorization — coverage requires approval before dispensing
    UseDenoted beside product entries to indicate PA requirement
    ConsequenceFailure to obtain PA may lead to claim denial
    inv-104: PA — Prior Authorization definition (re-iterated)
    PA (re-iterated)Prior Authorization — requires pre-approval prior to dispensing; appears in Requirements Limits
    Provider responsibilitySubmit supporting clinical information when requesting PA
    Denial riskClaims may be denied without required PA
    inv-105: QL — Quantity Limit (re-iterated)
    QL (re-iterated)Quantity Limit — maximum allowed quantity per specified time period (numeric or fractional per day)
    ExamplesShown as 'per 1 day' fractions or 'per 30 days' totals in product rows
    OverrideRequests above QL require documentation for medical necessity
    inv-106: S — Step therapy or supplemental requirement (re-iterated)
    S (re-iterated)Specialty designation/step/supplemental requirement used in the table to indicate specialty handling or program-specific rules
    ExamplesUsed for hepatitis C, oncology, and other specialty products (e.g., LEDIPASVIR-SOFOSBUVIR marked PA; S)
    Operational noteS may indicate specialty pharmacy routing or enrollment requirements
    inv-107: PA — Prior Authorization (definition)
    PAPrior Authorization — coverage requires approval prior to dispensing (definition)
    Table usageFlagged as PA in Requirements Limits column
    Provider actionObtain PA per payer procedures before dispensing for PA items
    inv-108: QL — Quantity Limit (definition)
    QL — definitionQuantity Limit — numeric maximum permitted within specified time period; shown per day or per 30 days
    FormatMay appear as absolute count (e.g., 15 per 30 days) or fractional per-day rate (e.g., 0.071 per 1 day)
    ReviewOverrides require medical necessity documentation
    inv-109: PA — Prior Authorization (definition repeated)
    PA (repeated)Prior Authorization — coverage requires approval before dispensing
    ImplicationPA appears as a Requirements Limits flag and triggers prior review
    DocumentationProviders must supply clinical rationale when seeking PA
    inv-110: QL — Quantity Limit (definition repeated)
    QL (repeated)Quantity Limit — maximum allowed units per specified time period; may be shown as per day or per 30 days
    ExamplesExamples include QL (1 per 1 day) or QL (60 per 30 days)
    Provider noteExceeding QL will prompt medical necessity review
    inv-111: S — Specialty designation (definition repeated)
    S — specialty designationIndicates specialty-managed product; specialty medicines require specialty pharmacy fills
    Benefit noteSpecialty medicines often covered under a different benefit than retail drugs
    Check planMembers/providers should verify specialty coverage via myHealthPartners or plan details
    inv-112: Prior Authorization required for coverage — PA
    PA requirementPrior Authorization required for coverage — products marked PA must have authorization before dispensing
    ConsequencesFailure to obtain PA may result in the medication not being covered under pharmacy benefits
    Provider actionSubmit PA per HealthPartners procedures with supporting clinical information
    inv-113: Quantity Limit (numerical limit per time period shown) — QL
    QL definitionQuantity Limit — numerical limit per time period shown in Requirements Limits (e.g., '4 per 30 days')
    DisplayQLs appear alongside product rows as per-day fractions or per-30-day totals
    Override processRequests exceeding QL reviewed for medical necessity and require documentation
    inv-114: Step therapy requirement — S
    S — step therapyIndicates a step therapy requirement where specified preferred medicines must be tried first
    Operational noteIf prior steps not met, prior approval is required before coverage at lower cost-share
    Table usageDenoted as 'S' or 'ST' in Requirements Limits for some products
    inv-115: Coverage references/conditions — ACA / SC references present in table header
    Coverage referencesACA / SC annotations appear in table header to indicate special coverage conditions (e.g., ACA-mandated preventive coverage)
    InterpretationRefer to table header and plan details to interpret ACA/SC annotations
    ExamplesVaccines and certain contraceptives are marked ACA in the formulary
    inv-116: QL — QL examples (4 per 30 days)
    Example QL valueQL 4 per 30 days (e.g., BAQSIMI, glucagon kits) — shown in the formulary table
    InterpretationQL values may be per 30 days for emergency medications and per day fractions for chronic injectables
    Provider actionAdhere to listed QL or submit documentation for exceptions
    inv-117: PA — PA = prior authorization required
    PA — summaryPA = prior authorization required (flag in Requirements Limits)
    ActionObtain pre-approval per payer processes; lack of PA may cause denial
    Where shownAppears next to many antiviral, specialty and other high-cost products in the formulary
    inv-118: S — specialty designation / pharmacy requirement
    S — specialty markerIndicates specialty designation, program or step requirement; may trigger specialty routing
    ExamplesUsed for some hepatitis C and oncology agents in Requirements Limits
    Provider implicationProducts marked S may require specialty pharmacy fill or program enrollment
    inv-119: PA — PA indicated in Requirements Limits
    PA indicator in tablePA is indicated in the Requirements Limits column for applicable products
    ImplicationWhen PA is present, coverage depends on prior approval
    Provider actionFollow payer PA submission processes and provide clinical justification
    inv-120: QL — Quantity Limit (e.g., 1 per 1 day)
    QL — numeric formatQuantity Limit entries such as '1 per 1 day' or fractional per-day values appear in Requirements Limits
    ExamplesSome stimulant or migraine therapies show fractional/day QLs (e.g., 0.429 per 1 day)
    Clinical noteQLs limit dispensed quantity; exceptions require documentation
    inv-121: S — Specialty drug designation appears in Requirements Limits
    S in Requirements LimitsS appears in Requirements Limits to denote specialty-managed products
    ExamplesAppears for oncology, biologic and other specialty agents
    Operational effectMay require specialty pharmacy dispensing or program enrollment
    inv-122: ACA — ACA-related coverage flag in Requirements Limits
    ACA mappingACA indicates Affordable Care Act-related coverage notation present in Requirements Limits for some agents
    UsageUsed for vaccines, contraceptives, smoking cessation products in table examples
    Coverage implicationACA-marked products may have mandated coverage per federal guidelines
    inv-123: Requirements Limits abbreviations — ACA, PA, QL mapping
    Abbreviations listRequirements Limits abbreviations include ACA, PA, QL (used in table to denote coverage/authorization rules)
    Interpretation adviceRefer to table header and plan documentation for full meaning and implications
    ExamplesACA — preventive; PA — prior authorization; QL — quantity limit
    inv-124: Requirements Limits codes — ACA, PA, QL, S explained
    Codes explainedRequirements Limits codes (ACA, PA, QL, S) indicate coverage restrictions such as ACA-mandated coverage, prior authorization, quantity limits, or specialty/site requirements
    Provider actionFollow the indicated requirement for each product row to determine coverage and authorization steps
    Where shownCodes appear in the Requirements Limits column throughout the formulary table

    Initial Therapy Criteria

    Step Therapy Rules

    Step therapy statementNotes / implication
    Try specified preferred medicines first
    A medicine with step therapy will be covered only if the member has already tried required prior medicine(s); if not, prior approval from HealthPartners is required before coverage at the lower cost-share.
    Step therapy / specialty flagExamples / implication
    'S' indicator present on some hepatitis C agents
    Examples include LEDIPASVIR‑SOFOSBUVIR and MAVYRET which are listed with Requirements Limits = PA; S, indicating specialty/step program requirements before coverage.
    Flag(s)Interpretation / example agents
    'TD' and 'S' flags on oncology/specialty agents
    Antineoplastic entries (e.g., abiraterone, everolimus) include PA; ONC; TD; S — indicating specialty distribution or program enrollment may be required as part of access prior to coverage.
    FlagCoverage implication / examples
    'TD' or 'ONC' flags for oncology agents
    Targeted cancer therapies (ROZLYTREK, TAGRISSO) and other oncology drugs show ONC or TD flags; these denote oncology benefit/specialty handling and may require specialty routing or program steps before coverage.
    DesignationMeaning / examples
    'S' designation on products
    Several products (for example AUSTEDO, EVRYSDI) carry 'S' indicating step therapy or specialty clinical edit applies and must be followed per formulary requirements.
    ObservationImplication
    No explicit step sequences listed in some sections
    Portions of the formulary list products with PA, QL, and Tier designations but do not provide step-by-step therapy algorithms; utilization management is implemented via PA, QL, and tiering where present.
    Step therapy flagExample / note
    'ST' indicated for some agents
    REPATHA SureClick and syringe entries are labeled ST; QL (0.071 per 1 day), indicating step therapy (ST) is required before coverage at the listed benefit level.
    'S' specialty/step markerExamples
    'S' required for certain specialty oral agents
    Examples include carglumic acid and deferasirox which are listed with Requirements Limits = PA; S, indicating specialty program or step requirements and that PA/submission is required.
    PA notedExamples (GLP‑1 / diabetes agents)
    Prior authorization indicated for several GLP‑1 / diabetes agents
    MOUNJARO, liraglutide and OZEMPIC entries are shown with Requirements Limits = PA and have numeric QL values (e.g., liraglutide QL 0.3 per 1 day), indicating PA applies for these agents.
    Coverage annotationImplication / examples
    'ACA' or 'S' on vaccines and biologics
    Some vaccines and biologics are annotated ACA (Affordable Care Act preventive coverage) or S (specialty); examples include AREXVY and PALFORZIA levels which show ACA or PA; S markings implying special coverage pathways or program requirements.
    ObservationInterpretation
    Step therapy often implied rather than explicit
    In many formulary sections step therapy is implied by tiering and presence of PA/S/QL flags; explicit step-by-step sequences are not present within the extracted chunks.

    Quantity Limits (Selected Items)

    Site of Care and Specialty Pharmacy Routing

    Billing Rule

    Fill specialty medicines at specialty pharmacy when required

    Certain specialty medicines and oncology drugs must be filled at a specialty pharmacy; prescribers should route prescriptions to the specialty pharmacy as indicated by the formulary.

    Note
    Billing Rule

    Follow 'S' specialty/site routing for ophthalmic products

    Some ophthalmic products include a specialty/site 'S' designation and may require specialty routing or site‑specific handling; follow the 'S' designation when submitting and routing prescriptions.

    Background

    The formulary groups medicines by therapeutic category and assigns cost-sharing tiers (Tier 1–7) to determine member out-of-pocket responsibility. Specialty medicines — typically high-cost products for chronic or complex conditions — are identified and commonly managed through specialty pharmacy channels and different benefit rules. The table uses requirement codes (for example PA = prior authorization; QL = quantity limit; ACA = Affordable Care Act preventive designation; S = specialty or step/program indicator) to convey administrative coverage requirements that affect how and when a specialty medicine will be covered.